Parker Waichman LLP

Tekturna To Undergo Canadian Safety Review

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions. “Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), Rasilez was associated with an increased risk of non-fatal […]

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions.

“Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), Rasilez was associated with an increased risk of non-fatal stroke, kidney complications, hyperkalemia (high levels of potassium in the blood), and low blood pressure,” Health Canada said, wrote CBC News. Tekturna is in a class of drugs known as direct rennin inhibitors, and is known generically as aliskiren, which is sold in Canada and elsewhere, under the brand name Rasilez.

When blood pressure increases to high levels, explained CBC News, the pressure forces the heart to work harder, increasing death risks from a number of causes, including heart disease and stroke. Tekturna is intended to reduce the body’s production of the enzyme renin, which has been shown to increase blood pressure.

Drug maker Novartis, announced it was halting the multinational clinical trial created to determine if adding Tektuma to tradition treatments in people diagnosed with Type 2 diabetes and kidney impairment could lower risks for cardiac and kidney problems, explained CBC News. Novartis also said it will stop marketing aliskiren for use with ACE-inhibitors and angiotensin receptor blockers until regulators determine if the aliskiren’s marketing license needs to be amended. Novartis said it is speaking with global health authorities about the implications of the trials findings, “As a precautionary measure Novartis will cease promotion of Rasilez/Tekturna-based products for use in combination with an ACE-inhibitor or ARB,” the company said, wrote CBC News.

Patients enrolled in the clinical trial—known as ALTITUDE—should speak with their study site for guidance and are advised not to cease treatment until they have spoken to their health care provider, said Novartis and Health Canada.

Trial participants either took aliskiren or a placebo, as well as whatever blood pressure medication they had been prescribed (either an ACE inhibitor or an angiotensin receptor blocker). The study was one of a number of large, costly trials Novartis funded in an attempt to broaden Tekturna and Rasilez use. The halted study is a major blow for Novartis, which said sales “are likely to be negatively impacted by the study results going forward.” Eric Althoff, a Novartis spokesman also said that the drug maker will review other, ongoing trial data. Novartis shares fell following the news.

Novartis launched Tekturna in 2007 for the treatment of high blood pressure, conducting a number of trials to determine if Tekturna could protect vital organs when taken for longer periods. The ceased trial involved 8,606 Type 2 diabetes patients at increased risk for heart or kidney failure and who took Tekturna in addition to receiving traditional heart treatment. Participants came from 36 countries, noted CBC News. The committee overseeing the study discovered greater-than-expected, unwanted adverse events once the drug was added to traditional treatments, including higher rates of nonfatal stroke, renal complications, and other problems. The committee also found the drug failed to prove more effective than a placebo.

Just prior, we wrote that Europe’s key drug regulator, the European Medicines Agency (EMA) announced it was initiating a review of aliskiren’s benefits and risks and had advised doctors to stop prescribing the medication to diabetic patients also taking older generation hypertension medications (ACE inhibitors, angiotensin receptor blockers).

We also previously wrote about a study published in the American Journal of Hypertension in 2007 that called into question the drug’s efficacy. The study, conducted at Weill Medical College of Cornell University in New York. “A review of six clinical trials of aliskiren involving 5,000 patients with mild to moderate hypertension indicated that this first of a new class of orally active antihypertensive drugs is no more effective than angiotensin-converting enzyme inhibitors (CEIs), angiotensin receptor blockers (ARBs), or diuretics for lowering blood pressure,” the authors wrote.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Michele josama at parker waichman is a wonderful and extremely polite person she has made my experience an easy and best experience ever I thank her from the bottom of my heart for all she has done. And I would highly recommend her to everyone I know. Parker waichman are extremely lucky to have her.
Maxine Fuentes
4 years ago
5 Star Reviews 150
I highly recommend Parker Waichman. Their staff Ashley, Jorge and Gina are very professional. I was really happy with their service.
Tonia Bailey
4 years ago
5 Star Reviews 150
I am very happy with the way Parker and Waichman is proceeding with my lawsuit. They clearly guided me through the process and answered all of my questions. One of the the things that I like the most about their administration is that they let you know right from the getgo, that before they making a decision, they need to study all possibilities of how to win the case, and that gave me the confidence assuring me that I made the right choice to hire Parker and Waichman. They have assigned Josephine Burgess to my case and I am impressed of how quickly she answer all my questions as well as helping me to promptly expedite my case, it is very ez to go through it with your help. Thank you Ms. Burgess because of your professionalism I understand that Parker and Waichman have an excellent team.
Miguel Boitel
5 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038